US20120283557A1 - Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses - Google Patents

Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses Download PDF

Info

Publication number
US20120283557A1
US20120283557A1 US13/464,949 US201213464949A US2012283557A1 US 20120283557 A1 US20120283557 A1 US 20120283557A1 US 201213464949 A US201213464949 A US 201213464949A US 2012283557 A1 US2012283557 A1 US 2012283557A1
Authority
US
United States
Prior art keywords
tissue
eye
laser
radiation
trabecular meshwork
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/464,949
Inventor
Michael S. Berlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20120283557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US13/464,949 priority Critical patent/US20120283557A1/en
Publication of US20120283557A1 publication Critical patent/US20120283557A1/en
Priority to US14/732,627 priority patent/US10064757B2/en
Priority to US16/008,917 priority patent/US10765559B2/en
Priority to US16/881,934 priority patent/US11039958B2/en
Priority to US17/302,965 priority patent/US11510813B2/en
Priority to US18/045,229 priority patent/US11857463B2/en
Priority to US18/356,590 priority patent/US20230355442A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F9/00825Methods or devices for eye surgery using laser for photodisruption
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F9/009Auxiliary devices making contact with the eyeball and coupling in laser light, e.g. goniolenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00844Feedback systems
    • A61F2009/00851Optical coherence topography [OCT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00861Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00865Sclera
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00861Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00868Ciliary muscles or trabecular meshwork
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00885Methods or devices for eye surgery using laser for treating a particular disease
    • A61F2009/00891Glaucoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00897Scanning mechanisms or algorithms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F9/00825Methods or devices for eye surgery using laser for photodisruption
    • A61F9/0084Laser features or special beam parameters therefor

Definitions

  • the present invention pertains generally to methods and procedures for use in ophthalmic surgery. More particularly, the present invention pertains to the use of laser devises for photodisruption tissue in the eye. The present invention is particularly, but not exclusively, useful for an ophthalmic surgical procedure involving transcorneal or fiberoptic photodisruption of tissue of the corneo scleral angle as a treatment for glaucoma.
  • Glaucoma refers to a series of relatively common eye disorders in which pressure within the eye is sufficiently high as to result in damage to sensitive intraocular structures, including the retina and optic nerve. Glaucomas are classified as primary (including chronic open angle glaucoma, angle closure glaucoma, mixed mechanism.
  • glaucoma and infantile glaucoma and secondary relate to other diseases of the eye.
  • the elevation of intraocular pressure ultimately leads to irreversible destruction of the optic nerve.
  • the clinical symptoms which are not readily recognized in the early stages, are characterized mainly by a slow, relentless, progressive narrowing of the field of vision, and decrement in visual integration processing, including diminished dark adaptation. In the absence of treatment, the eventual outcome is total loss of vision often accompanied by severe eye pain.
  • the outer layer of the eye includes a sclera 17 that serves as a supporting framework for the eye.
  • the front of the sclera includes a cornea 15 , a transparent tissue that enables light to enter the eye.
  • An anterior chamber 7 is located between the cornea 15 and the crystalline lens 4 .
  • the anterior chamber 7 contains a constantly flowing clear fluid called aqueous humor 1 .
  • the crystalline lens 4 is connected to the eye by fiber zonules, which are connected to the cilliary body 3 .
  • an iris 19 encircles the outer perimeter of the lens 4 and includes a pupil 5 at its center. The diameter of the pupil 5 controls the amount of light passing through the lens 4 to the retina 8 .
  • a posterior chamber 2 is located between the crystalline lens 4 and the retina 8 .
  • the anatomy of the eye also includes a trabecular meshwork 9 , a narrow band of spongy tissue within the eye that encircles the iris 19 .
  • the trabecular meshwork (“TM”) varies in shape and is microscopic in size. It is generally triangular in cross-section, varying in thickness from about 100 ⁇ m to 200 ⁇ m. It is made up of different fibrous layers, having micro-sized pores forming fluid pathways for the egress of aqueous humor from the anterior chamber.
  • the trabecular meshwork 9 has been measured to a thickness of about 100 ⁇ m at its anterior edge, Schwalbe's line, 18 at the approximate juncture of cornea 15 and sclera 17 .
  • the trabecular meshwork widens to about 200 ⁇ m at its base where it and the iris 19 attach to the scleral spur.
  • the passageway through the pores in the trabecular meshwork 9 lead through a very thin, porous tissue called the juxtacanalicular trabecular meshwork 13 , which in turn abuts the interior side of a structure called Schlemm's canal 11 .
  • Schlemm's canal 11 is filled with a mixture of aqueous humor and blood components and branches off into collector channels 12 that drain the aqueous humor into the venous system.
  • any obstruction in the trabecular meshwork, the juxtacanalicular trabecular meshwork or Schlemm's canal prevents the aqueous humor from readily escaping from the anterior chamber. This results in an elevation of intraocular pressure in the eye. Increased intraocular pressure can lead to damage of the optic nerve and eventual blindness.
  • Lasers were first used in 1965 to repair retinal detachments.
  • the procedure involved chorioretinal coagulation in which a laser beam positioned from without the eye was used to achieve fusion of the retina and the choroid.
  • the technique consisted of introducing a laser beam from outside the cornea, and by employing the refractive media of the eye itself, the laser radiation was directed in such a manner that it was concentrated at a selected point upon the retina/choroid so that the tissues in a very localized area were photothermally congealed.
  • the high photon energies of femtosecond lasers can photodisrupt the material in question, namely eye tissue, in a manner which does not cause significant target tissue temperature elevation.
  • both visible and infrared femtosecond laser radiation can be used to drastically alter the target tissue in a “cold” environment. This becomes significant for controlled removal of organic substances, such as living tissue, in contradistinction to treatments in which heat is generated, e.g. by thermal lasers, which could damage, if not destroy, delicate eye tissue adjacent to the target sites to be removed and thereby induce healing responses.
  • Femtosecond (“FS”) lasers used for this purpose include the group of rapidly pulsed lasers which emit at 0.4 to 2.5 ⁇ m in the visible and infrared spectra.
  • the high energy photons from femtosecond lasers at photodisruptive fluence levels are absorbed by the target tissues. This absorption creates a hot plasma at the focus, vaporizing tissue. The plasma subsequently expands supersonically launching a pressure wave. Later, a cavitation bubble forms and eventually collapses. The extent of the tissue damage caused by the pressure wave and cavitation bubble expansion is energy-dependent. Femtosecond pulses deposit very little energy while still causing breakdown, therefore producing surgical photodisruption while minimizing collateral damage.
  • Femtosecond laser photodisruption of human trabecular meshwork an in vitro study; Exp. Eye Res. 2005; 81(3); 298-305, disclosed the use of FS lasers to perform photodisruption of human TM strips ex vivo, creating all-thickness ablation channels through the TM without collateral damage.
  • the ideal settings for creating lesions with minimal collateral side effects on the inner surface of the TM are: Ti:Sapphire laser beam (45 fsec, 1 kHz 800 nm) with 14.4 mJ pulse enemy and an exposure time of 0.5 sec Nakamura H, Liu Y, Witt T E, et Femtosecond laser photodisruption of primate trabecular meshwork: an ex vivo study; invest. Ophthalmol. Vis. Sci. 2009; 1198-204 disclosed photodisruption by FS laser of the TM of ex vivo, intact, enucleated human and baboon eyes.
  • the settings were 45 fsec, 1 kHz, 800 nm with 60 to 480 ⁇ J and 0.001 to 0.3 see exposure time.
  • the study showed that laser ablation of the TM oh inferno in ex vivo primate eyes is feasible by a custom femtosecond laser ablation system with a gonioscopic lens. The photodisruption did not reach Schlemm's canal, although this goal could easily be achieved through an alteration in laser settings and delivery methods.
  • successful use of ultrashort laser pulses, such as those produced by a FS laser in vivo to produce channels in the TM to relieve glaucoma has not been demonstrated by the work discussed above and presents challenges not present in those experimental studies.
  • the laser beam must be delivered to a precise location on the TM in such a way as to avoid damage to adjacent and intervening tissue.
  • the challenges of delivering adequate photodisruptive energy in precise patterns in shapes and depths include (a) the curved surface of the target, (b) the target lies beyond the critical angle of visible ocular structures seen through the cornea unaided, (c) optical coupling systems are necessary to visualize and target the intended treatment sites, e.g.
  • the location of Schlemm's canal may be difficult to establish particularly as it lies behind the optically significant trabecular meshwork, (e) once the inner wall of Schlemm's canal therefore the “blood aqueous barrier”, is penetrated, blood components may obscure the optical pathway for any future optical viewing and/or treating beams.
  • the present disclosure provides for the delivery of photodisruptive fluence levels of visible or infrared photons to the precise point of the target tissue of the eye by direct or fiberoptic delivery systems without impinging upon the overlying or surrounding tissue or upon the tissue at the region of beam entry into the eye for the purpose of effecting removal of select tissue in precise shapes and depths.
  • Ultrashort laser pulses are directed into the eye either through the cornea or ab internally via fibers to enable laser radiation, including visible and infrared radiation, under gonioscopic control or through fiberoptic elements, including fiber lasers, thereby effecting precisely controlled photodisruptive removal of such target tissue of the corneo scleral angle.
  • Such tissue may include TM, juxtacanalicular TM, and portions of Schlemm's canal, collector channels, aqueous veins and sclera.
  • a laser with pulse duration in the range from 20 fs to 300 ps is used, although it is to be recognized that even shorter pulse durations may be used.
  • the laser uses an optical coupling to affect controlled photodisruption of the target.
  • FIG. 1 is a schematic sectional view of an eye illustrating the interior anatomical structure.
  • FIG. 2 is a perspective fragmentary view of the anatomy within the anterior chamber of an eye, depicting the corneoscleral angle
  • FIG. 3 is a schematic sectional view of an eye with an attached indirect goniolens with an interior mirror.
  • the goniolens is attached to the sclera via suction or mechanical devices.
  • FIG. 4 is a schematic sectional view of an eye with an attached indirect goniolens with an interior mirror.
  • the goniolens is attached to the cornea via suction or mechanical devices.
  • FIG. 5 is a schematic sectional view of an eye with an attached direct goniolens with an external mirror system.
  • the mirror and lens are attached via retaining systems to the sclera.
  • FIG. 6 is a schematic sectional view of an eye illustrating a fiber-optic probe disposed next to the trahecular meshwork in the anterior chamber of the eye.
  • FIG. 7 is a fragmentary cross section of the anatomy within the anterior chamber of an eye, showing a segment of target tissue to be photodisrupted.
  • the present disclosure provides for the delivery of photodisruptive fluence levels of visible or infrared photons to the precise point of the target tissue of the eye by direct or fiberoptic delivery systems without impinging upon the overlying or surrounding tissue or upon the tissue at the region of beam entry into the eye for the purpose of effecting removal of select tissue in precise shapes and depths.
  • Ultrashort laser pulses are directed into the eye either through the cornea or ab internally via fibers to enable laser radiation, including visible and infrared radiation, under gonioscopic control or through fiberoptic elements, including fiber lasers, thereby effecting precisely controlled photodisruptive removal of such target tissue of the corneo scleral angle.
  • Such tissue may include TM, juxtacanalicular TM, and portions of Schlemm's canal, collector channels, aqueous veins and sclera.
  • a laser with pulse duration in the range from 20 fs to 300 ps is used, although it is to he recognized that even shorter pulse durations may he used.
  • the laser uses an optical coupling to affect controlled photodisruption of the target.
  • a coupling system employs a goniolens or an ab interno fiberoptic that precisely targets the outflow obstructing tissues to effect removal of the outflow obstruction.
  • targeting may include localization of Schlemm's canal, detected optically or otherwise, such as by OCT (optical coherence tomography) or photoaccoustic spectroscopy.
  • the optical system may also include features to enhance visualization of Schlemm's canal by controlling localized and diffuse pressure gradients, for example by creating relative hypotomy to induce blood reflux into Schlemm's canal.
  • Means of coupling the globe of the eye optically to the laser beam delivery system may be included to enable the extraordinar precision of the photodisruptive laser.
  • Such systems include goniolens flange systems, including coupling capabilities such as suction, with diameters in the range of 10 to 25 mm, fluidic chambers both to control intraocular pressure (“IOP”) and to maintain corneal clarity and shape.
  • IOP intraocular pressure
  • suction means for similar purposes which, in addition, extremelyly control light energy delivery registration to the target tissues.
  • the fiber may have multiple channels to control intraocular pressure, to enable visualization and optical coupling to Schlemm's canal.
  • the procedure for creating openings in the trabecular meshwork comprises:
  • IOP is altered to affect this optical pathway, which is lowered to allow targeting of Schlemm's canal then elevated to prevent blood reflux.
  • laser energy is applied gonioscopically transcorneal or directed through the fiberoptic element.
  • the deflecting mirror may be stationary or may have elements to adjust the mirror within the goniolens delivery system both to precisely target the subject tissue and to precisely direct femtosecond laser energy to these tissues.
  • Such a minor may be mechanically controllable to effect scanning.
  • the gonioscope is coupled to the eye by various means, including prongs, clips, suction, viscoelastic, aqueous solution and inflatable balloons.
  • the laser delivery system is also coupled both to the goniolens and via the goniolens to the target cornea-scleral angle tissues. The optical delivery is stabilized through precise control of the goniolens and goniolens mirror position and control of the femtosecond laser energy delivered to the target tissue by sensors which detect precise laser tissue interactions as they occur.
  • the systems may include image stabilization to enable precise laser coupling to the docked goniolens device which includes a mirroring/light deflecting system to enable viewing and treating the cornea scleral angle structure at the laser delivery system, at the goniolens or fiber or both.
  • a goniolens is applied to the cornea and a laser beam is focused on the target tissue.
  • a fiberoptic handpiece is passed through an incision in the eye where it is stabilized and secured to the globe and the laser beam is focused on the target tissue.
  • a multidimensional mobile reflective surface e.g., Mylar balloon
  • This system can include fluidics to control temperature within the lens system.
  • This configuration also may include concurrent illuminating beams and treatment beams with image capture for pixel to pixel image matching to control precise targeting when coupled to a mobile or curved target.
  • DLP Digital Light Processing
  • the system is capable of detecting cardiac cycle pulsation and the filling and emptying causing choroid translation of outflow structures by optical or ultrasound techniques, coupling the detection system to the optical delivery system to enable precise photo disruption of target tissue by means of a combination or individually: (a) mechanically controlled mirror, (h) piezoelectric controlled mirror, (c) DLP optical semiconductor, (d) surface reflecting fluid balloons (e.g. Mylar) included at the laser and/or within a gonioscopic delivery system.
  • the goniolens air/surface optics are either plano or concave or convex.
  • the mirror/light reflecting element optics are either plano, concave, convex, complex curved or in a segmented mirror array.
  • Light altering materials include variable optical density fluid lair filled balloons, glass, plastic or metal shaped to enable photodisruption to occur at target regions which are both beyond the critical angle to the corneal surface and are curved, residing on the inner surface of a globe.
  • the laser beam emitted from the laser source may be parallel, convergent or divergent and it is altered by the lens mirror system to enable all forms of emitted beams to focus with a suprathreshold photodisruptive fluence at the target tissue.
  • the goniolens includes a pressure detection means to compensate for cardiac cycle translation of the entire globe/orbit structures/choroid and intraocular structures including detection of choroidal filling and emptying from cardiac cycle events, which may include pressure detectors in the goniolens or goniolens flange and software in the laser delivery system to compensate for this target translation to enable precise target photodisruption on the moving target.
  • a concentric ring system may be used to enable (1) registration either through suction or through a retaining mechanical device (prongs, corkscrew) (2) IOP control (3) ocular pulsation detection.
  • a bladder/balloon system may he used to control optical surfaces, including cornea and any internal mirroring surfaces to enable an emitter to best couple to the target tissue.
  • the cornea may be compressed (e.g. flattened) or the goniolens corneal surface may be curved and coupled to the corneal surface by optically neutral fluidic means, liquids and gels.
  • the direct goniolens is retained in a holding device coupled to an optic delivery system with mirror external to the goniolens.
  • Such external mirroring enables the laser source and viewing optics to be inclined at angles from 10° to 170°, often 60° to 120° and most often 80° to 110° in relation to the target tissue.
  • the optical delivery is stabilized through precise control of the fiber position and control of the femtosecond laser energy delivered from the fiber tip by sensors which detect precise fiber tip position and alignment to the target tissue.
  • the photodisruptive radiation is directed to the target tissues, namely corneoscleral angle structures comprising trabecular meshwork, juxtacanalicular trabecular meshwork, components of Schlemm's canal, and in some cases adjacent cornea, sclera, and iris structures to create fluid passageways between the anterior chamber of the eye and Schlemm's canal or alternatively the suprascleral/subTenon space or alternatively the suprachoroidal space.
  • Photodisruptive laser energy is targeted to gonioscleral angle structures for the purpose of removing tissue which impedes aqueous outflow or to redirect outflow. Openings are created by patterns of adjacent photodisruption regions in this tissue.
  • the patterns consist of various shapes in size ranging from surface dimensions of 20 to 200 microns and depth adequate to penetrate the inner wall of Schlemm's canal. Patterning enables openings to be created individually, sequentially or several concurrently. In one iteration, when concurrently, the depth, is controlled at each opening to allow the creation of craters without entering SC until all craters are at a depth after which minimal additional tissue removal would enter SC thus enabling the optical pathway in the anterior chamber to remain clear. Only at this time would SC be perforated at each crater concurrently to minimize optical pathway obscuration by blood reflux from SC.
  • the present invention minimizes healing and increases longevity of improved outflow at the site of filtration.
  • the present invention enables a significantly greater opportunity for success, including the ability to titrate the amount of photodisruptive energy necessary to result in a measured lowering of intraocular pressure.
  • FIG. 6 is a side sectional view of the interior anatomy of a human eye showing fiber-optic probe 23 in relation to an embodiment of a method of treating glaucoma.
  • a small self sealing incision 14 can be created in the cornea 15 with a surgical blade or femtosecond laser or other device.
  • the anterior chamber can be further stabilized with a viscoelastic agent.
  • Fiber optic probe 23 can then be positioned and advanced in the incision 14 into the anterior chamber 7 to target the trabecular meshwork immediately or ab interno or a distal end of fiber-optic probe 23 contacts or is substantially adjacent to the target tissue for removal.
  • Fiber optic probe 23 may be manually directed or held rigid in relation to the ocular structures via anchoring to the globe, sclera 17 or cornea 15 through devices which may include prongs 56 which also may hold in place a pressure regulating system 55 and an ocular pulse sensing system 54 .
  • Laser energy is delivered from the distal end of fiber-optic probe 23 targeting the trabecular meshwork across the anterior chamber or in contact or adjacent to the tissues sufficient to cause photodisruption.
  • Tissues to be removed include the trabecular meshwork 9 , the juxtacanalicular trabecular meshwork 13 and an inner wall of Schlemm's canal 11 .
  • Fiber-optic probe 23 delivered photodisruptive energy creates an aperture in the proximal inner wall of Schlemm's canal 11 but does not perforate the distal outer wail.
  • additional apertures can be created in the trabecular meshwork and the target tissue following reposition of the probe.
  • the resultant aperture or apertures are effective to restore relatively normal rates of drainage of aqueous humor.
  • FIG. 3 shows an optical delivery system consisting of an indirect goniolens 50 attached to the sclera 17 mechanically or by prongs 56 or suction, with an internal mirror 52 .
  • the mirror may be individual or segmented and fixed or mobile to enable scanning for both viewing and for treatment targeting.
  • the mirror 52 can be controlled mechanically or pneumatically or with a Mylar type surface reflecting balloon.
  • the mirror can be plano, concave, convex and singular or in a segmented array.
  • a beam 51 of pulsed radiation is generated by a femtosecond laser and delivered into the eye by the delivery system, including the goniolens 50 .
  • the beam 51 is reflected by a mirror 52 which may be controlled by a servo system 53 connected to a controller 58 to focus scanning photodisruptive energy onto the curved surface of the target tissue.
  • the optics enable bidirectional use, one direction is used to treat the target tissue, the other direction is used to view and/or sense the x, y, z coordinates of the targeted tissue to enable precise treatment and removal of the target regions.
  • the beam 51 has a set of pulse parameter ranges specifically selected to photodisrupt targeted tissue of the trabecular meshwork, while minimizing damage to surrounding tissue.
  • the beam has a wavelength between 0.4 and 2.5 microns.
  • the exact wavelength used for a particular subject depends on tradeoffs between strong absorption by the meshwork and transmission of preceding ocular structures and aqueous humor.
  • FIG. 4 shows an indirect goniolens 50 attached to the cornea 15 mechanically 56 or by suction with an internal mirror 52 .
  • FIG. 5 shows a direct goniolens attached to the sclera 17 by suction 57 or mechanically with a mirror system 52 external to the goniolens.
  • the pulse duration of the laser beam is chosen to have a high probability of photodisrupting material of the corneoscleral angle outflow tissues. There is an inverse relationship between the laser pulse duration and the energy required in each pulse to generate optical breakdown.
  • the pulse duration is selected to be shorter than the thermal relaxation of the target so that only the targeted material is heated and the surrounding tissue is unaffected. Thus, the pulse duration is between 20 fs and 300 ps.
  • the pulse rate is between 1 and 500 KHz.
  • the pulse energy is chosen to facilitate photodisruption and minimize the shockwave effect of the laser light.
  • a typical value for the pike energy is between 300 to 1500 nJ.
  • the spot diameter is chosen such that sufficient laser energy density is provided to facilitate photodisruption of the trabecular meshwork tissue.
  • the spot size is between 1 to 10 microns.
  • the goniolens 50 is anchored either on the sclera 17 or the cornea 15 by a suction ring 57 or prongs 56 .
  • the anchoring system is attached to a pressure regulating system 55 and an ocular pulse sensing system 54 .
  • the anchoring system is either concentric 57 or segmented 56 . Scanning the spot in the x,y, and z direction effects patterns for tissue removal.
  • FIG. 7 shows the target tissue to be photodisrupted in a perspective view 70 and in a cross sectional view 71 .
  • a single site is demonstrated but understood is duplication of this site over several regions individually or concurrently.
  • the TM may be approached ab externo via the semi-transparent sclera using high numerical aperture optics and a fundamental wavelength that allows deep penetration through the sclera.
  • the coupling lens could be planar or curved.
  • All coupling lenses, goniolenses and fibers require focusing devices at the laser which couple optically to the lenses, goniolenses and fibers to effect appropriate fluences at the target tissue to effect micro ablations and thereby tissue removal.
  • the procedure for ultrashort laser pulse trabeculostomy comprises the steps that follow.

Abstract

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be effected under gonioscopic control. Internal delivery may he controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application is based, in part, on U.S. provisional application No. 61/482,824 entitled TREATMENT SYSTEMS, DEVICES AND METHODS FOR THE FEMTOSECOND VISIBLE AND INFRARED LASER LIGHT TREATMENT OF GLAUCOMA, filed May 5, 2011, which is hereby incorporated by reference in its entirety.
  • FIELD OF THE INVENTION
  • The present invention pertains generally to methods and procedures for use in ophthalmic surgery. More particularly, the present invention pertains to the use of laser devises for photodisruption tissue in the eye. The present invention is particularly, but not exclusively, useful for an ophthalmic surgical procedure involving transcorneal or fiberoptic photodisruption of tissue of the corneo scleral angle as a treatment for glaucoma.
  • BACKGROUND OF THE INVENTION
  • Glaucoma refers to a series of relatively common eye disorders in which pressure within the eye is sufficiently high as to result in damage to sensitive intraocular structures, including the retina and optic nerve. Glaucomas are classified as primary (including chronic open angle glaucoma, angle closure glaucoma, mixed mechanism.
  • glaucoma and infantile glaucoma and secondary (related to other diseases of the eye). The elevation of intraocular pressure ultimately leads to irreversible destruction of the optic nerve. The clinical symptoms, which are not readily recognized in the early stages, are characterized mainly by a slow, relentless, progressive narrowing of the field of vision, and decrement in visual integration processing, including diminished dark adaptation. In the absence of treatment, the eventual outcome is total loss of vision often accompanied by severe eye pain.
  • In order to fully appreciate the described embodiments, a brief overview of the anatomy of the eye is provided. As schematically shown in FIG. 1, the outer layer of the eye includes a sclera 17 that serves as a supporting framework for the eye. The front of the sclera includes a cornea 15, a transparent tissue that enables light to enter the eye. An anterior chamber 7 is located between the cornea 15 and the crystalline lens 4. The anterior chamber 7 contains a constantly flowing clear fluid called aqueous humor 1. The crystalline lens 4 is connected to the eye by fiber zonules, which are connected to the cilliary body 3. In the anterior chamber 7, an iris 19 encircles the outer perimeter of the lens 4 and includes a pupil 5 at its center. The diameter of the pupil 5 controls the amount of light passing through the lens 4 to the retina 8. A posterior chamber 2 is located between the crystalline lens 4 and the retina 8.
  • As shown in FIG. 2, the anatomy of the eye also includes a trabecular meshwork 9, a narrow band of spongy tissue within the eye that encircles the iris 19. The trabecular meshwork (“TM”) varies in shape and is microscopic in size. It is generally triangular in cross-section, varying in thickness from about 100 μm to 200 μm. It is made up of different fibrous layers, having micro-sized pores forming fluid pathways for the egress of aqueous humor from the anterior chamber. The trabecular meshwork 9 has been measured to a thickness of about 100 μm at its anterior edge, Schwalbe's line, 18 at the approximate juncture of cornea 15 and sclera 17.
  • The trabecular meshwork widens to about 200 μm at its base where it and the iris 19 attach to the scleral spur. The passageway through the pores in the trabecular meshwork 9 lead through a very thin, porous tissue called the juxtacanalicular trabecular meshwork 13, which in turn abuts the interior side of a structure called Schlemm's canal 11. Schlemm's canal 11 is filled with a mixture of aqueous humor and blood components and branches off into collector channels 12 that drain the aqueous humor into the venous system. Because aqueous humor is continuously produced by the eye, any obstruction in the trabecular meshwork, the juxtacanalicular trabecular meshwork or Schlemm's canal, prevents the aqueous humor from readily escaping from the anterior chamber. This results in an elevation of intraocular pressure in the eye. Increased intraocular pressure can lead to damage of the optic nerve and eventual blindness.
  • Present surgical techniques to lower intraocular pressure include procedures enabling fluid to drain from within the eye to extra ocular sites. However, these drainage or “filtering” procedures not only increase the risk of causing a lens cataract, but often fail by virtue of their closure resulting from the healing of the very wound created for gaining access to the surgical site. Ab interno surgical procedures, also, if not adequately stealth eventually fail. In creating the egress by photoablation or by photodisruption less inflammation at the egress site is induced than by current techniques, thus prolonging filtration wound, function.
  • Lasers were first used in 1965 to repair retinal detachments. The procedure involved chorioretinal coagulation in which a laser beam positioned from without the eye was used to achieve fusion of the retina and the choroid. The technique consisted of introducing a laser beam from outside the cornea, and by employing the refractive media of the eye itself, the laser radiation was directed in such a manner that it was concentrated at a selected point upon the retina/choroid so that the tissues in a very localized area were photothermally congealed.
  • In contrast to thermal energy produced by visible and by infrared lasers, such as Nd:YAG systems, the high photon energies of femtosecond lasers can photodisrupt the material in question, namely eye tissue, in a manner which does not cause significant target tissue temperature elevation. By photodisruption, both visible and infrared femtosecond laser radiation can be used to drastically alter the target tissue in a “cold” environment. This becomes significant for controlled removal of organic substances, such as living tissue, in contradistinction to treatments in which heat is generated, e.g. by thermal lasers, which could damage, if not destroy, delicate eye tissue adjacent to the target sites to be removed and thereby induce healing responses.
  • Femtosecond (“FS”) lasers used for this purpose include the group of rapidly pulsed lasers which emit at 0.4 to 2.5 μm in the visible and infrared spectra. In contrast to the thermal visible and infrared radiation from some Nd:YAG or CO2lasers or the like, the high energy photons from femtosecond lasers at photodisruptive fluence levels are absorbed by the target tissues. This absorption creates a hot plasma at the focus, vaporizing tissue. The plasma subsequently expands supersonically launching a pressure wave. Later, a cavitation bubble forms and eventually collapses. The extent of the tissue damage caused by the pressure wave and cavitation bubble expansion is energy-dependent. Femtosecond pulses deposit very little energy while still causing breakdown, therefore producing surgical photodisruption while minimizing collateral damage.
  • Juhasz T, Chai D, Chaudhary G, et al.; Application of Femtosecond Laser Surgery for the Treatment of Glaucoma; in Frontiers in Optics, OSA Technical Digest (CD) (Optical Society of America, 2008) disclosed that FS laser pulses could be used to create partial thickness scleral channels that drain aqueous humor into the sub-conjunctival space, showing potential for the treatment of glaucoma. Toyran S, Liu Y, Singha S., et al.;
  • Femtosecond laser photodisruption of human trabecular meshwork: an in vitro study; Exp. Eye Res. 2005; 81(3); 298-305, disclosed the use of FS lasers to perform photodisruption of human TM strips ex vivo, creating all-thickness ablation channels through the TM without collateral damage. The ideal settings for creating lesions with minimal collateral side effects on the inner surface of the TM are: Ti:Sapphire laser beam (45 fsec, 1 kHz 800 nm) with 14.4 mJ pulse enemy and an exposure time of 0.5 sec Nakamura H, Liu Y, Witt T E, et Femtosecond laser photodisruption of primate trabecular meshwork: an ex vivo study; invest. Ophthalmol. Vis. Sci. 2009; 1198-204 disclosed photodisruption by FS laser of the TM of ex vivo, intact, enucleated human and baboon eyes. The settings were 45 fsec, 1 kHz, 800 nm with 60 to 480 μJ and 0.001 to 0.3 see exposure time. The study showed that laser ablation of the TM oh inferno in ex vivo primate eyes is feasible by a custom femtosecond laser ablation system with a gonioscopic lens. The photodisruption did not reach Schlemm's canal, although this goal could easily be achieved through an alteration in laser settings and delivery methods. However, successful use of ultrashort laser pulses, such as those produced by a FS laser, in vivo to produce channels in the TM to relieve glaucoma has not been demonstrated by the work discussed above and presents challenges not present in those experimental studies. In particular, the laser beam must be delivered to a precise location on the TM in such a way as to avoid damage to adjacent and intervening tissue. The challenges of delivering adequate photodisruptive energy in precise patterns in shapes and depths include (a) the curved surface of the target, (b) the target lies beyond the critical angle of visible ocular structures seen through the cornea unaided, (c) optical coupling systems are necessary to visualize and target the intended treatment sites, e.g. trabecular meshwork and Schlemm's canal, (d) the location of Schlemm's canal may be difficult to establish particularly as it lies behind the optically significant trabecular meshwork, (e) once the inner wall of Schlemm's canal therefore the “blood aqueous barrier”, is penetrated, blood components may obscure the optical pathway for any future optical viewing and/or treating beams.
  • SUMMARY OF THE INVENTION
  • The present disclosure provides for the delivery of photodisruptive fluence levels of visible or infrared photons to the precise point of the target tissue of the eye by direct or fiberoptic delivery systems without impinging upon the overlying or surrounding tissue or upon the tissue at the region of beam entry into the eye for the purpose of effecting removal of select tissue in precise shapes and depths. Ultrashort laser pulses are directed into the eye either through the cornea or ab internally via fibers to enable laser radiation, including visible and infrared radiation, under gonioscopic control or through fiberoptic elements, including fiber lasers, thereby effecting precisely controlled photodisruptive removal of such target tissue of the corneo scleral angle. Such tissue may include TM, juxtacanalicular TM, and portions of Schlemm's canal, collector channels, aqueous veins and sclera. Preferably, a laser with pulse duration in the range from 20 fs to 300 ps is used, although it is to be recognized that even shorter pulse durations may be used. The laser uses an optical coupling to affect controlled photodisruption of the target.
  • It is to be understood that this summary is provided as a means for generally determining what follows in the drawings and detailed description, and is not intended to limit the scope of the invention. The foregoing and other objects, features and advantages of the invention will be readily understood upon consideration of the following detailed description taken in conjunction with the accompanying drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The foregoing summary of this disclosure as well as the following detailed descriptions of the embodiments is further understood when read in conjunction with the accompanying drawings, which are included by way of example, and not by way of limitation with regard to this disclosure.
  • FIG. 1 is a schematic sectional view of an eye illustrating the interior anatomical structure.
  • FIG. 2 is a perspective fragmentary view of the anatomy within the anterior chamber of an eye, depicting the corneoscleral angle
  • FIG. 3 is a schematic sectional view of an eye with an attached indirect goniolens with an interior mirror. The goniolens is attached to the sclera via suction or mechanical devices.
  • FIG. 4 is a schematic sectional view of an eye with an attached indirect goniolens with an interior mirror. The goniolens is attached to the cornea via suction or mechanical devices.
  • FIG. 5 is a schematic sectional view of an eye with an attached direct goniolens with an external mirror system. The mirror and lens are attached via retaining systems to the sclera.
  • FIG. 6 is a schematic sectional view of an eye illustrating a fiber-optic probe disposed next to the trahecular meshwork in the anterior chamber of the eye.
  • FIG. 7 is a fragmentary cross section of the anatomy within the anterior chamber of an eye, showing a segment of target tissue to be photodisrupted.
  • DETAILED DESCRIPTION EMBODIMENTS OF THE INVENTION
  • The present disclosure provides for the delivery of photodisruptive fluence levels of visible or infrared photons to the precise point of the target tissue of the eye by direct or fiberoptic delivery systems without impinging upon the overlying or surrounding tissue or upon the tissue at the region of beam entry into the eye for the purpose of effecting removal of select tissue in precise shapes and depths. Ultrashort laser pulses are directed into the eye either through the cornea or ab internally via fibers to enable laser radiation, including visible and infrared radiation, under gonioscopic control or through fiberoptic elements, including fiber lasers, thereby effecting precisely controlled photodisruptive removal of such target tissue of the corneo scleral angle. Such tissue may include TM, juxtacanalicular TM, and portions of Schlemm's canal, collector channels, aqueous veins and sclera. Preferably, a laser with pulse duration in the range from 20 fs to 300 ps is used, although it is to he recognized that even shorter pulse durations may he used. The laser uses an optical coupling to affect controlled photodisruption of the target.
  • A coupling system employs a goniolens or an ab interno fiberoptic that precisely targets the outflow obstructing tissues to effect removal of the outflow obstruction. Such targeting may include localization of Schlemm's canal, detected optically or otherwise, such as by OCT (optical coherence tomography) or photoaccoustic spectroscopy.
  • The optical system may also include features to enhance visualization of Schlemm's canal by controlling localized and diffuse pressure gradients, for example by creating relative hypotomy to induce blood reflux into Schlemm's canal. Means of coupling the globe of the eye optically to the laser beam delivery system may be included to enable the exquisite precision of the photodisruptive laser. Such systems include goniolens flange systems, including coupling capabilities such as suction, with diameters in the range of 10 to 25 mm, fluidic chambers both to control intraocular pressure (“IOP”) and to maintain corneal clarity and shape. To enable optical pathways, such as planar surface to enable precision targeting, suction means for similar purposes which, in addition, exquisitely control light energy delivery registration to the target tissues. In the case of the fiber laser, the fiber may have multiple channels to control intraocular pressure, to enable visualization and optical coupling to Schlemm's canal.
  • Preferably, the procedure for creating openings in the trabecular meshwork comprises:
  • (1) imaging the target tissue, (2) locking a pattern to the image, (3) creating the pattern and controlling the depth of laser penetration, and (4) maintaining IOP to enable visualization of Schlemm's canal and concurrently controlling egress of blood to prevent optical decoupling of light obstruction for subsequent laser delivery to target tissue.
  • Several 20 to 200 μm partial depth openings may be created concurrently without complete penetration to prevent blood reflux or other optical pathway obscuring elements after which Schlemm's canal inner wall penetration is effected to all sites concurrently.
  • IOP is altered to affect this optical pathway, which is lowered to allow targeting of Schlemm's canal then elevated to prevent blood reflux.
  • Gonioscopic an fiberoptic delivery systems for laser surgery in the eye wherein thermal and/or radiation damage to the eye is minimized are disclosed.
  • In connection with glaucoma treatment, laser energy is applied gonioscopically transcorneal or directed through the fiberoptic element. When gonioscopic, the deflecting mirror may be stationary or may have elements to adjust the mirror within the goniolens delivery system both to precisely target the subject tissue and to precisely direct femtosecond laser energy to these tissues. Such a minor may be mechanically controllable to effect scanning. The gonioscope is coupled to the eye by various means, including prongs, clips, suction, viscoelastic, aqueous solution and inflatable balloons. The laser delivery system is also coupled both to the goniolens and via the goniolens to the target cornea-scleral angle tissues. The optical delivery is stabilized through precise control of the goniolens and goniolens mirror position and control of the femtosecond laser energy delivered to the target tissue by sensors which detect precise laser tissue interactions as they occur.
  • The systems may include image stabilization to enable precise laser coupling to the docked goniolens device which includes a mirroring/light deflecting system to enable viewing and treating the cornea scleral angle structure at the laser delivery system, at the goniolens or fiber or both.
  • In one embodiment a goniolens is applied to the cornea and a laser beam is focused on the target tissue. In another embodiment, a fiberoptic handpiece is passed through an incision in the eye where it is stabilized and secured to the globe and the laser beam is focused on the target tissue.
  • In one goniolens configuration, a multidimensional mobile reflective surface (e.g., Mylar balloon) is moved (horizontally, vertical and in depth) by inflation or deflation. This system can include fluidics to control temperature within the lens system. This configuration also may include concurrent illuminating beams and treatment beams with image capture for pixel to pixel image matching to control precise targeting when coupled to a mobile or curved target.
  • In another goniolens configuration DLP (Digital Light Processing) optical semiconductors or equivalent are used to control the gonioscopic delivery.
  • In yet another configuration, the system is capable of detecting cardiac cycle pulsation and the filling and emptying causing choroid translation of outflow structures by optical or ultrasound techniques, coupling the detection system to the optical delivery system to enable precise photo disruption of target tissue by means of a combination or individually: (a) mechanically controlled mirror, (h) piezoelectric controlled mirror, (c) DLP optical semiconductor, (d) surface reflecting fluid balloons (e.g. Mylar) included at the laser and/or within a gonioscopic delivery system.
  • The goniolens air/surface optics are either plano or concave or convex. The mirror/light reflecting element optics are either plano, concave, convex, complex curved or in a segmented mirror array. Light altering materials include variable optical density fluid lair filled balloons, glass, plastic or metal shaped to enable photodisruption to occur at target regions which are both beyond the critical angle to the corneal surface and are curved, residing on the inner surface of a globe.
  • The laser beam emitted from the laser source may be parallel, convergent or divergent and it is altered by the lens mirror system to enable all forms of emitted beams to focus with a suprathreshold photodisruptive fluence at the target tissue.
  • In one configuration, the goniolens includes a pressure detection means to compensate for cardiac cycle translation of the entire globe/orbit structures/choroid and intraocular structures including detection of choroidal filling and emptying from cardiac cycle events, which may include pressure detectors in the goniolens or goniolens flange and software in the laser delivery system to compensate for this target translation to enable precise target photodisruption on the moving target.
  • A concentric ring system may be used to enable (1) registration either through suction or through a retaining mechanical device (prongs, corkscrew) (2) IOP control (3) ocular pulsation detection.
  • A bladder/balloon system may he used to control optical surfaces, including cornea and any internal mirroring surfaces to enable an emitter to best couple to the target tissue. In coupling the cornea, the cornea may be compressed (e.g. flattened) or the goniolens corneal surface may be curved and coupled to the corneal surface by optically neutral fluidic means, liquids and gels.
  • In the case of a direct (e.g. non mirror) goniolens delivery system the direct goniolens is retained in a holding device coupled to an optic delivery system with mirror external to the goniolens. Such external mirroring enables the laser source and viewing optics to be inclined at angles from 10° to 170°, often 60° to 120° and most often 80° to 110° in relation to the target tissue.
  • In the moving eye goniolens complex the laser fires only when the target is optically captured and stabilized. These optical coupling mechanisms enable precise photodisruption at the target tissue in space and in depth.
  • In the case of an ab interno fiber, the optical delivery is stabilized through precise control of the fiber position and control of the femtosecond laser energy delivered from the fiber tip by sensors which detect precise fiber tip position and alignment to the target tissue.
  • The photodisruptive radiation is directed to the target tissues, namely corneoscleral angle structures comprising trabecular meshwork, juxtacanalicular trabecular meshwork, components of Schlemm's canal, and in some cases adjacent cornea, sclera, and iris structures to create fluid passageways between the anterior chamber of the eye and Schlemm's canal or alternatively the suprascleral/subTenon space or alternatively the suprachoroidal space.
  • Photodisruptive laser energy is targeted to gonioscleral angle structures for the purpose of removing tissue which impedes aqueous outflow or to redirect outflow. Openings are created by patterns of adjacent photodisruption regions in this tissue. The patterns consist of various shapes in size ranging from surface dimensions of 20 to 200 microns and depth adequate to penetrate the inner wall of Schlemm's canal. Patterning enables openings to be created individually, sequentially or several concurrently. In one iteration, when concurrently, the depth, is controlled at each opening to allow the creation of craters without entering SC until all craters are at a depth after which minimal additional tissue removal would enter SC thus enabling the optical pathway in the anterior chamber to remain clear. Only at this time would SC be perforated at each crater concurrently to minimize optical pathway obscuration by blood reflux from SC.
  • In other iterations, in which the IOP is regulated to prevent blood reflux from SC, other patterning options are used, to create individual openings or several concurrent openings in from 1 to 12 clock hours of the angle.
  • Surgical trauma to the outer wall of Schlemm's canal, or in the case of full thickness penetration to the overlying conjunctival and Tenon's tissue, all extremely subject to scarring, is thereby minimized. This is in contrast to current procedures which result in more scarring of sensitive ocular structures and therefore more rapid failure of procedures whose purpose is to control IOP.
  • By minimizing trauma while creating an aqueous humor egress route, the present invention minimizes healing and increases longevity of improved outflow at the site of filtration. The present invention enables a significantly greater opportunity for success, including the ability to titrate the amount of photodisruptive energy necessary to result in a measured lowering of intraocular pressure.
  • Referring to FIG. 6, an overview of a method of operating a fiber-optic laser delivery system for treatment of glaucoma or other eye conditions follows: FIG. 6 is a side sectional view of the interior anatomy of a human eye showing fiber-optic probe 23 in relation to an embodiment of a method of treating glaucoma. After applying local and/or peri retrobular anesthesia, a small self sealing incision 14 can be created in the cornea 15 with a surgical blade or femtosecond laser or other device. The anterior chamber can be further stabilized with a viscoelastic agent. Fiber optic probe 23 can then be positioned and advanced in the incision 14 into the anterior chamber 7 to target the trabecular meshwork immediately or ab interno or a distal end of fiber-optic probe 23 contacts or is substantially adjacent to the target tissue for removal. Fiber optic probe 23 may be manually directed or held rigid in relation to the ocular structures via anchoring to the globe, sclera 17 or cornea 15 through devices which may include prongs 56 which also may hold in place a pressure regulating system 55 and an ocular pulse sensing system 54.
  • Laser energy is delivered from the distal end of fiber-optic probe 23 targeting the trabecular meshwork across the anterior chamber or in contact or adjacent to the tissues sufficient to cause photodisruption. Tissues to be removed include the trabecular meshwork 9, the juxtacanalicular trabecular meshwork 13 and an inner wall of Schlemm's canal 11. Fiber-optic probe 23 delivered photodisruptive energy creates an aperture in the proximal inner wall of Schlemm's canal 11 but does not perforate the distal outer wail. In some embodiments, additional apertures can be created in the trabecular meshwork and the target tissue following reposition of the probe. Thus by removing outflow obstructing tissues, the resultant aperture or apertures are effective to restore relatively normal rates of drainage of aqueous humor.
  • Referring to FIGS. 3-5, an overview of a method of surgical gonioscopic delivery systems for the treatment of glaucoma or other eye conditions follows: FIG. 3 shows an optical delivery system consisting of an indirect goniolens 50 attached to the sclera 17 mechanically or by prongs 56 or suction, with an internal mirror 52. The mirror may be individual or segmented and fixed or mobile to enable scanning for both viewing and for treatment targeting. In the condition of a mobile mirror/mirror surface, the mirror 52 can be controlled mechanically or pneumatically or with a Mylar type surface reflecting balloon. The mirror can be plano, concave, convex and singular or in a segmented array.
  • A beam 51 of pulsed radiation is generated by a femtosecond laser and delivered into the eye by the delivery system, including the goniolens 50. The beam 51 is reflected by a mirror 52 which may be controlled by a servo system 53 connected to a controller 58 to focus scanning photodisruptive energy onto the curved surface of the target tissue. The optics enable bidirectional use, one direction is used to treat the target tissue, the other direction is used to view and/or sense the x, y, z coordinates of the targeted tissue to enable precise treatment and removal of the target regions. The beam 51 has a set of pulse parameter ranges specifically selected to photodisrupt targeted tissue of the trabecular meshwork, while minimizing damage to surrounding tissue. Thus, the beam has a wavelength between 0.4 and 2.5 microns. The exact wavelength used for a particular subject depends on tradeoffs between strong absorption by the meshwork and transmission of preceding ocular structures and aqueous humor. FIG. 4 shows an indirect goniolens 50 attached to the cornea 15 mechanically 56 or by suction with an internal mirror 52. FIG. 5 shows a direct goniolens attached to the sclera 17 by suction 57 or mechanically with a mirror system 52 external to the goniolens.
  • The pulse duration of the laser beam is chosen to have a high probability of photodisrupting material of the corneoscleral angle outflow tissues. There is an inverse relationship between the laser pulse duration and the energy required in each pulse to generate optical breakdown. The pulse duration is selected to be shorter than the thermal relaxation of the target so that only the targeted material is heated and the surrounding tissue is unaffected. Thus, the pulse duration is between 20 fs and 300 ps. The pulse rate is between 1 and 500 KHz.
  • The pulse energy is chosen to facilitate photodisruption and minimize the shockwave effect of the laser light. A typical value for the pike energy is between 300 to 1500 nJ.
  • The spot diameter is chosen such that sufficient laser energy density is provided to facilitate photodisruption of the trabecular meshwork tissue. The spot size is between 1 to 10 microns.
  • The goniolens 50 is anchored either on the sclera 17 or the cornea 15 by a suction ring 57 or prongs 56. The anchoring system is attached to a pressure regulating system 55 and an ocular pulse sensing system 54. The anchoring system is either concentric 57 or segmented 56. Scanning the spot in the x,y, and z direction effects patterns for tissue removal.
  • FIG. 7 shows the target tissue to be photodisrupted in a perspective view 70 and in a cross sectional view 71. In this case a single site is demonstrated but understood is duplication of this site over several regions individually or concurrently.
  • Alternatively, the TM may be approached ab externo via the semi-transparent sclera using high numerical aperture optics and a fundamental wavelength that allows deep penetration through the sclera. This produces targeted ablation of the deep cornea scleral angle structures, specifically targeting TM, JCTM and portions of Schlemm's Canal. In this instance the coupling lens could be planar or curved.
  • All coupling lenses, goniolenses and fibers require focusing devices at the laser which couple optically to the lenses, goniolenses and fibers to effect appropriate fluences at the target tissue to effect micro ablations and thereby tissue removal.
  • Preferably, the procedure for ultrashort laser pulse trabeculostomy comprises the steps that follow.
      • 1. Prepare patient for femto laser trabeculostomy procedure.
      • 2. Prepare femto laser which has been pretested on a model of trabecular meshwork for accuracy and fluence at the target tissue.
      • 3. Align goniolens with optical alignment system of laser visualization system to target planned trabecular meshwork tissue sites and lock the target into the system for treatment.
      • 4. In the case where the goniolens mirror is not stationary, but mobile, assure the tracking system is engaged to control all optical surfaces.
      • 5. Secure the goniolens onto the eye. This may be pneumatic or physical engagement to control all movement and enable tracking system to engage and apply energy only when target is precisely focused for appropriate delivery of laser energy to the target sites. If mobile, laser will only engage when precise target alignment assures exact tissue targeting in x, y and z loci.
      • 6. Anchor the goniolens either on the cornea or the sclera either by prongs or a suction ring.
      • 7. Attach anchoring system to a pressure regulating system and an ocular pulse sensing system.
      • 8. In the case where cardiac cyclic translation of target is monitored and controlled, engage this system to enable precise depth targeting.
      • 9. Couple end of optical pathway to a femto second laser.
      • 10. Locate Schlemm's canal with the gonioscope.
      • 11. The goniolens mirror may be curved to allow targeting of curved trabecular meshwork.
      • 12. Focus laser beam on target tissue.
      • 13. Photodisrupt target tissue until crater forms adjacent to Schlemm's canal.
      • 14. Repeat step 14. up to 10 times in a pattern, for example, from 5 o'clock to 1 o'clock.
      • 15. The patterns consist of various shapes in size ranging from surface dimensions of 20 to 200 microns and depth adequate to penetrate the inner wall of Schlemm's canal.
      • 16. Using the laser, concurrently extend craters so they become ostia into Schlemm's canal.
      • 17. Detach gonioscope
      • 18. In the case where femto laser energy is delivered fiberoptically within the eye, all above apply. In addition, following paracentesis and stabilization of the anterior chamber with aqueous and/or viscoelastic agents, the fiberoptic delivery system is placed into the anterior chamber and imaging of all relevant structures is performed to assure targeting to planned sites. The fiber and fiber position maintaining devices are engaged and enabled, manually and/or automatically
  • The terms and expressions which have been employed in the foregoing specification are used therein as terms of description and not of limitation, and there is no intention, in the use of such terms and expressions, to exclude equivalents of the features shown and described or portions thereof, it being recognized that the scope of the invention is defined and limited only by the claims that follow.

Claims (19)

1. A method of creating an opening in the trabecular meshwork of an eye of a patient, comprising:
producing ultrashort laser pulses whose fundamental wavelength is in the range of infrared through visible light;
propagating the ultrashort laser pulses through a high numerical aperture optic so as to produce a focused beam of light; and
guiding the beam of light through the eye tissue enclosing the anterior chamber of the eye to focus at a selected location on the trabecular meshwork of the eye.
2. An apparatus for creating an opening in the trabecular meshwork of an eye of a patient, comprising:
an ultrashort pulse generating laser having a fundamental wavelength in the range of infrared through visible light;
a high numerical aperture optic coupled to the laser to produce a focused beam of ultrashort pukes generated by the laser;
a goniolens adapted to be fixedly attached to the cornea of an eye; and
a guidance optic fixedly attached to the goniolens for guiding the beam of ultrashort laser pulses; and
a guidance system connected to the guidance optic to move the optic and thereby guide the beam through the eye tissue enclosing the anterior Chamber of the eye to focus at a selected location on the trabecular meshwork of the eye.
3. The apparatus of claim 2 further comprising a goniolens mechanical stabilization system having prongs that attach to the cornea.
4. The apparatus of claim 2 further comprising goniolens mechanical stabilization system having prongs that attach to the limbus region
5. A method of creating and maintaining an opening in a trabecular meshwork of a patient's eye to conduct fluid from an anterior chamber to Schlemm's canal of the eye, comprising:
passing one end of a fiberoptic element through a small perforation in an outermost encapsulating tissue of the eyeball until said one end of said fiberoptic element penetrates into the eye's anterior chamber;
immobilizing and stabilizing said fiberoptic element to maintain precise focus to the target tissue, or
transocularly advancing said one end of the fiberoptic element through the said anterior chamber until the penetrating end of said fiberoptic element is juxtaposed immediately adjacent targeted eye tissue to be treated; and
coupling the opposite end of said fiberoptic element to a photodisruptive laser emitting radiation selected from the class consisting of (1) visible or infrared femtosecond laser radiation having a wavelength of 0.4 to 2.5 microns and at a fluence level sufficient to produce tissue disruption and focusing
the radiation being emitted from the tip of the fiberoptic element upon the target tissue; and
subjecting the adjacent targeted tissue to photodisruption from the radiation while maintaining the end of said fiberoptic element to effect photochemical removal of said target tissue.
6. The method of claim 5 wherein the targeted tissue is intermediate an irido-corneal angle of the eye at a level of trabecular meshwork tissue thereof.
7. The method of claim 5 comprising applying the laser pulses to form at least one of a drain channel or a humor outflow opening.
8. The method of claim 5 wherein the photodisruptive laser is selected from the class emitting (1) visible femtosecond radiation having a wavelength of between about 0.4-1.4 micron and (2) infrared femtosecond radiation having a wavelength of 1.5 to 2.5 microns.
9. A method of creating and maintaining an opening in a trabecular meshwork of a patient's eye to conduct fluid from an anterior chamber to Schlemm's canal of the eye, comprising:
focusing the laser beam transcorneal under gonioscopic control on the target tissue;
coupling the opposite end of the optical pathway to a photodisruptive laser emitting radiation selected from the class consisting of (1) visible or infrared femtosecond laser radiation having a wavelength of 0.4 to 2.5 microns and at a fluence level sufficient to produce photochemical tissue disruption and focusing the radiation upon the target tissue and
subjecting the targeted tissue to photodisruption from the laser radiation such that photodisruption is patterned to effect tissue removal with minimal surrounding tissue perturbation.
10. The method of claim 9 wherein the targeted tissue is intermediate an irido-corneal angle of the eye at a level of trabecular meshwork tissue thereof.
11. The method of claim 9 comprising applying the laser pulses to form at least one of a drain channel or a humor outflow opening.
12. A method for surgical treatment of the eye by laser radiation comprising the steps of:
passing one end of a fiberoptic element through a small perforation in an outermost encapsulating tissue of the eyeball until said one end of said fiberoptic element penetrates into the eye's anterior chamber;
immobilizing and stabilizing said fiberoptic element to maintain precise focus to the target tissue; or
transocularly advancing said one end of the fiberoptic element through the said anterior chamber until the penetrating end of said fiberoptic element is juxtaposed immediately adjacent targeted eye tissue to be treated; and
coupling the opposite end of said fiberoptic element to a photodisruptive laser emitting radiation selected from the class consisting of (1) visible or infrared femtosecond laser radiation having a wavelength of 0.4 to 2.5 microns and at a fluence level sufficient to produce tissue disruption and focusing
the radiation being emitted from the tip of the fiberoptic element upon the target tissue; and
subjecting the adjacent targeted tissue to photodisruption from the radiation while maintaining the end of said fiberoptic element to effect removal of said target tissue.
13. A method for surgical treatment of the eye by laser radiation comprising the steps of:
focusing the laser beam transcorneal under gonioscopic control on the target tissue;
coupling the opposite end of the laser optic to a photodisruptive laser emitting radiation selected from the class consisting of (1) visible or infrared femtosecond laser radiation having a wavelength of 0.4 to 2.5 microns and at a fluence level sufficient to produce tissue disruption and focusing the radiation
being emitted upon the target tissue; and
subjecting the targeted tissue to photodisruption from the laser radiation, such that photodisruption is patterned to effect tissue removal with minimal surrounding tissue perturbation.
14. The method of claim 13 wherein the duration of each laser pulse is in the range of approximately 20 fs-300 ps.
15. The method of claim 14 whereby a transcorneal delivery system effects the outflow of aqueous humor through the trabecular meshwork, juxtacanalicular trabecular meshwork and inner wall of Schlemm's canal.
14. The method of claim 13 whereby a transcorneal delivery system effects the outflow of aqueous humor through the trabecular meshwork, juxtacanalicular trabecular meshwork and inner wall of Schlemm's canal.
15. A method of using an optical coupling to enable controlled photodisruptions at the target tissue
16. The method of claim 15, wherein the coupling system of the goniolens controls the intraocular pressure in targeting Schlemm's canal,
17. The method of claim 11 where Schlemm's canal is detected optically or by optical coherence tomography (OCT) or by photoaccoustic spectroscopy.
US13/464,949 2011-05-05 2012-05-04 Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses Abandoned US20120283557A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US13/464,949 US20120283557A1 (en) 2011-05-05 2012-05-04 Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US14/732,627 US10064757B2 (en) 2011-05-05 2015-06-05 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US16/008,917 US10765559B2 (en) 2011-05-05 2018-06-14 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US16/881,934 US11039958B2 (en) 2011-05-05 2020-05-22 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US17/302,965 US11510813B2 (en) 2011-05-05 2021-05-17 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US18/045,229 US11857463B2 (en) 2011-05-05 2022-10-10 Methods for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US18/356,590 US20230355442A1 (en) 2011-05-05 2023-07-21 Methods and systems for the treatment of glaucoma using visible and infrared ultrashort laser pulses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482824P 2011-05-05 2011-05-05
US13/464,949 US20120283557A1 (en) 2011-05-05 2012-05-04 Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/732,627 Continuation US10064757B2 (en) 2011-05-05 2015-06-05 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses

Publications (1)

Publication Number Publication Date
US20120283557A1 true US20120283557A1 (en) 2012-11-08

Family

ID=47090691

Family Applications (7)

Application Number Title Priority Date Filing Date
US13/464,949 Abandoned US20120283557A1 (en) 2011-05-05 2012-05-04 Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses
US14/732,627 Active US10064757B2 (en) 2011-05-05 2015-06-05 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US16/008,917 Active US10765559B2 (en) 2011-05-05 2018-06-14 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US16/881,934 Active US11039958B2 (en) 2011-05-05 2020-05-22 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US17/302,965 Active US11510813B2 (en) 2011-05-05 2021-05-17 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US18/045,229 Active 2032-06-07 US11857463B2 (en) 2011-05-05 2022-10-10 Methods for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US18/356,590 Pending US20230355442A1 (en) 2011-05-05 2023-07-21 Methods and systems for the treatment of glaucoma using visible and infrared ultrashort laser pulses

Family Applications After (6)

Application Number Title Priority Date Filing Date
US14/732,627 Active US10064757B2 (en) 2011-05-05 2015-06-05 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US16/008,917 Active US10765559B2 (en) 2011-05-05 2018-06-14 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US16/881,934 Active US11039958B2 (en) 2011-05-05 2020-05-22 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US17/302,965 Active US11510813B2 (en) 2011-05-05 2021-05-17 Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US18/045,229 Active 2032-06-07 US11857463B2 (en) 2011-05-05 2022-10-10 Methods for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US18/356,590 Pending US20230355442A1 (en) 2011-05-05 2023-07-21 Methods and systems for the treatment of glaucoma using visible and infrared ultrashort laser pulses

Country Status (1)

Country Link
US (7) US20120283557A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130204236A1 (en) * 2011-12-01 2013-08-08 Nanophthalmos, Llc Method and system for laser ocular surgery
US20130226159A1 (en) * 2012-02-28 2013-08-29 Ziemer Ophthalmic Systems Ag Ophthalmological patient interface device
WO2014149772A3 (en) * 2013-03-15 2014-12-31 Amo Development, Llc. Hybrid ophthalmic interface apparatus
CN105050556A (en) * 2013-02-26 2015-11-11 贝尔金激光有限公司 System for glaucoma treatment
US9554940B2 (en) 2012-03-26 2017-01-31 Glaukos Corporation System and method for delivering multiple ocular implants
US9572963B2 (en) 2001-04-07 2017-02-21 Glaukos Corporation Ocular disorder treatment methods and systems
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US9642746B2 (en) 2001-05-21 2017-05-09 Michael Berlin Glaucoma surgery methods and systems
US9820883B2 (en) 2000-05-19 2017-11-21 Michael S. Berlin Method for treating glaucoma
WO2018049359A1 (en) * 2016-09-12 2018-03-15 University Of Rochester Glaucoma surgery visualization apparatus
US9962290B2 (en) 2006-11-10 2018-05-08 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US9993368B2 (en) 2000-04-14 2018-06-12 Glaukos Corporation System and method for treating an ocular disorder
US10064757B2 (en) 2011-05-05 2018-09-04 Michael S. Berlin Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
WO2018232397A1 (en) 2017-06-16 2018-12-20 Berlin Michael S Methods and systems for oct guided glaucoma surgery
US10258233B2 (en) * 2016-04-29 2019-04-16 Drug Delivery Company, Llc Non-sliding and non-sutured contact lens system for ophthalmic procedures
USD846738S1 (en) 2017-10-27 2019-04-23 Glaukos Corporation Implant delivery apparatus
US10285856B2 (en) 2001-08-28 2019-05-14 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US10363168B2 (en) 2011-06-14 2019-07-30 Ivantis, Inc. Ocular implants for delivery into the eye
US10363169B2 (en) 2010-05-10 2019-07-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. System and method for treating an eye
US10485701B2 (en) 2002-04-08 2019-11-26 Glaukos Corporation Devices and methods for glaucoma treatment
WO2020018436A1 (en) * 2018-07-16 2020-01-23 The Regents Of The University Of California Surgical treatment for glaucoma
JP2020507416A (en) * 2017-02-15 2020-03-12 イリデックス・コーポレーション Method for treating an eye using a wide area light source and an eye mask device
WO2020050916A1 (en) * 2018-09-07 2020-03-12 Vialase, Inc. Surgical system and procedure for precise intraocular pressure reduction
WO2020050915A1 (en) * 2018-09-07 2020-03-12 Vialase, Inc. Non-invasive and minimally invasive laser surgery for the reduction of intraocular pressure in the eye
CN111110440A (en) * 2018-10-12 2020-05-08 北京弘健医疗器械有限公司 Device for performing scleral surgical procedures
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
US10779990B2 (en) 2017-02-17 2020-09-22 EyeMDengineering LLC Ophthalmic incisional procedure instrument and method
US10821024B2 (en) 2018-07-16 2020-11-03 Vialase, Inc. System and method for angled optical access to the irido-corneal angle of the eye
US10821023B2 (en) 2018-07-16 2020-11-03 Vialase, Inc. Integrated surgical system and method for treatment in the irido-corneal angle of the eye
US20200352785A1 (en) * 2018-07-16 2020-11-12 Vialase, Inc. Method, system, and apparatus for imaging and surgical scanning of the irido-corneal angle for laser surgery of glaucoma
US10993840B2 (en) 2017-06-16 2021-05-04 Michael S. Berlin Methods and systems for OCT guided glaucoma surgery
US11026836B2 (en) 2012-04-18 2021-06-08 Ivantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US11039746B1 (en) 2016-04-29 2021-06-22 Drug Delivery Company, Llc Non-sliding and non-sutured contact lens system for ophthalmic procedures
US11058582B2 (en) 2019-07-01 2021-07-13 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US20210235986A1 (en) * 2020-02-04 2021-08-05 Vialase, Inc. System and method for locating a surface of ocular tissue for glaucoma surgery based on dual aiming beams
US11135088B2 (en) 2011-12-19 2021-10-05 Ivantis Inc. Delivering ocular implants into the eye
US11197779B2 (en) 2015-08-14 2021-12-14 Ivantis, Inc. Ocular implant with pressure sensor and delivery system
US11246754B2 (en) 2018-07-16 2022-02-15 Vialase, Inc. Surgical system and procedure for treatment of the trabecular meshwork and Schlemm's canal using a femtosecond laser
WO2022056073A1 (en) * 2020-09-11 2022-03-17 ContactRx LLC Ophthalmic illumination device
US11376040B2 (en) 2017-10-06 2022-07-05 Glaukos Corporation Systems and methods for delivering multiple ocular implants
US11382794B2 (en) 2018-07-02 2022-07-12 Belkin Laser Ltd. Direct selective laser trabeculoplasty
EP3893824A4 (en) * 2018-12-13 2022-09-21 IOPtima Ltd. Methods and systems for laser assisted technology for minimally-invasive ab-interno glaucoma surgery
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery
US11612315B2 (en) 2020-04-09 2023-03-28 Vialase, Inc. Alignment and diagnostic device and methods for imaging and surgery at the irido-corneal angle of the eye
US11712369B2 (en) 2012-11-28 2023-08-01 Alcon Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
US11744734B2 (en) 2007-09-24 2023-09-05 Alcon Inc. Method of implanting an ocular implant
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11771596B2 (en) 2010-05-10 2023-10-03 Ramot At Tel-Aviv University Ltd. System and method for treating an eye
AU2020401393A1 (en) * 2019-12-14 2022-08-04 Vialase, Inc. Near eye reflective devices for diagnostic and therapeutic ophthalmic procedures
US20230029661A1 (en) * 2020-02-07 2023-02-02 Ellex Medical Pty Ltd Direct laser trabeculoplasty method and apparatus

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199149A1 (en) * 1996-03-21 2004-10-07 Myers Raymond I. Lenticular refractive surgery of presbyopia, other refractive errors, and cataract retardation
US20060050229A1 (en) * 2003-04-07 2006-03-09 Arkadiy Farberov Universal gonioscope-contact lens system for intraocular laser surgery
US20080027519A1 (en) * 2006-07-28 2008-01-31 Guerrero John M Method of treatment of ocular compartment syndromes
US20080082078A1 (en) * 2001-05-21 2008-04-03 Eyelight, Inc. Glaucoma surgery methods and systems
US20080091224A1 (en) * 2006-07-11 2008-04-17 Refocus Group, Inc. Apparatus and method for securing ocular tissue
US20090157062A1 (en) * 2007-12-13 2009-06-18 Christoph Hauger Systems and methods for treating glaucoma and systems and methods for imaging a portion of an eye
US20090281530A1 (en) * 2005-06-13 2009-11-12 Technolas Perfect Vision Gmbh Messerschmittstrasse 1+3 Method for treating an organic material
US20100036488A1 (en) * 2008-04-04 2010-02-11 Forsight Labs, Llc Therapeutic device for pain management and vision

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3884236A (en) 1971-10-28 1975-05-20 Mikhail M Krasnov Method of glaucoma treatment
US3858577A (en) 1974-04-05 1975-01-07 Univ Southern California Fiber optic laser light delivery system
US3982541A (en) 1974-07-29 1976-09-28 Esperance Jr Francis A L Eye surgical instrument
US4273109A (en) 1976-07-06 1981-06-16 Cavitron Corporation Fiber optic light delivery apparatus and medical instrument utilizing same
DE3069080D1 (en) 1979-11-28 1984-10-04 Lasag Ag Observation device for eye-treatment
NO147900C (en) 1981-03-12 1983-07-06 Finn Skjaerpe MICROSURGICAL INSTRUMENT.
JPS589111U (en) 1981-07-07 1983-01-21 住友電気工業株式会社 laser scalpel
US4497319A (en) 1981-10-28 1985-02-05 Nippon Infrared Industries Co., Ltd. Laser irradiating apparatus
US4633866A (en) 1981-11-23 1987-01-06 Gholam Peyman Ophthalmic laser surgical method
US4583539A (en) 1982-01-12 1986-04-22 Cornell Research Foundation, Inc. Laser surgical system
US4461294A (en) 1982-01-20 1984-07-24 Baron Neville A Apparatus and process for recurving the cornea of an eye
US4470407A (en) 1982-03-11 1984-09-11 Laserscope, Inc. Endoscopic device
US4551129A (en) 1983-04-08 1985-11-05 Coleman D Jackson Technique and apparatus for intraocular and microsurgery including lighter-irrigator hypodermic tube
US4559942A (en) 1984-02-29 1985-12-24 William Eisenberg Method utilizing a laser for eye surgery
US4558698A (en) 1984-03-01 1985-12-17 Dell Lawrence W O Laser canaliculostomy eye-treatment
US4671273A (en) 1984-03-19 1987-06-09 Lindsey Ernest J Laser hand piece, for use in opthalmic, plastic, and ear, nose, and throat surgery
US4538608A (en) 1984-03-23 1985-09-03 Esperance Jr Francis A L Method and apparatus for removing cataractous lens tissue by laser radiation
US4580559A (en) 1984-07-24 1986-04-08 Esperance Francis A L Indirect ophthalmoscopic photocoagulation delivery system for retinal surgery
US4994060A (en) 1984-09-17 1991-02-19 Xintec Corporation Laser heated cautery cap with transparent substrate
US4722350A (en) 1984-09-21 1988-02-02 Armeniades C D Ophthalmic instrument for measuring intraocular fluid pressure
US4660546A (en) 1984-11-07 1987-04-28 Robert S. Herrick Method for treating for deficiency of tears
US4658816A (en) 1984-11-14 1987-04-21 Concept Incorporated Lighted canaliculus intubation sets
US5034010A (en) 1985-03-22 1991-07-23 Massachusetts Institute Of Technology Optical shield for a laser catheter
US4770654A (en) 1985-09-26 1988-09-13 Alcon Laboratories Inc. Multimedia apparatus for driving powered surgical instruments
US4791927A (en) 1985-12-26 1988-12-20 Allied Corporation Dual-wavelength laser scalpel background of the invention
US4729373A (en) 1986-12-18 1988-03-08 Peyman Gholam A Laser-powered surgical device with a vibrating crystalline tip
US4846172A (en) 1987-05-26 1989-07-11 Berlin Michael S Laser-delivery eye-treatment method
DE3726524A1 (en) 1987-08-10 1989-02-23 Fresenius Ag HAEMOGLOBIN DETECTOR
US4876250A (en) 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
DE3831141A1 (en) 1988-09-13 1990-03-22 Zeiss Carl Fa METHOD AND DEVICE FOR MICROSURGERY ON EYE BY LASER RADIATION
US5990099A (en) 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5371078A (en) 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5092837A (en) 1989-12-20 1992-03-03 Robert Ritch Method for the treatment of glaucoma
US5129895A (en) 1990-05-16 1992-07-14 Sunrise Technologies, Inc. Laser sclerostomy procedure
US5254112A (en) 1990-10-29 1993-10-19 C. R. Bard, Inc. Device for use in laser angioplasty
US5722970A (en) 1991-04-04 1998-03-03 Premier Laser Systems, Inc. Laser surgical method using transparent probe
US5300020A (en) 1991-05-31 1994-04-05 Medflex Corporation Surgically implantable device for glaucoma relief
US5359685A (en) 1991-06-21 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Focusing tips for optical fibers
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5360399A (en) 1992-01-10 1994-11-01 Robert Stegmann Method and apparatus for maintaining the normal intraocular pressure
EP0634947B1 (en) 1992-04-10 2001-12-19 Surgilight,Inc. Apparatus for performing eye surgery
US5273056A (en) 1992-06-12 1993-12-28 Alcon Laboratories, Inc. Use of combinations of viscoelastics during surgery
US5643250A (en) 1992-08-07 1997-07-01 O'donnell, Jr.; Francis E. Laser probe hand piece
US5772597A (en) 1992-09-14 1998-06-30 Sextant Medical Corporation Surgical tool end effector
US5993438A (en) 1993-11-12 1999-11-30 Escalon Medical Corporation Intrastromal photorefractive keratectomy
US5445637A (en) 1993-12-06 1995-08-29 American Cyanamid Company Method and apparatus for preventing posterior capsular opacification
WO1995029737A1 (en) 1994-05-03 1995-11-09 Board Of Regents, The University Of Texas System Apparatus and method for noninvasive doppler ultrasound-guided real-time control of tissue damage in thermal therapy
US6102045A (en) 1994-07-22 2000-08-15 Premier Laser Systems, Inc. Method and apparatus for lowering the intraocular pressure of an eye
US5704907A (en) 1994-07-22 1998-01-06 Wound Healing Of Oklahoma Method and apparatus for lowering the intraocular pressure of an eye
US5811453A (en) 1994-12-23 1998-09-22 Alcon Laboratories, Inc. Viscoelastic compositions and methods of use
US5607966A (en) 1994-12-23 1997-03-04 Alcon Laboratories, Inc. Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory prodrugs
US5738676A (en) 1995-01-03 1998-04-14 Hammer; Daniel X. Laser surgical probe for use in intraocular surgery
WO1996020742A1 (en) 1995-01-06 1996-07-11 Wong Vernon G Improve eye implant for relief of glaucoma
US5792103A (en) 1995-02-03 1998-08-11 Schwartz; Daniel M. Viscosurgical method and apparatus
US6059772A (en) 1995-03-10 2000-05-09 Candela Corporation Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure
US7892226B2 (en) 1995-03-20 2011-02-22 Amo Development, Llc. Method of corneal surgery by laser incising a contoured corneal flap
US5865831A (en) 1996-04-17 1999-02-02 Premier Laser Systems, Inc. Laser surgical procedures for treatment of glaucoma
US5895831A (en) 1996-12-04 1999-04-20 Uop Llc Solid catalyst alkylation process
GB9700390D0 (en) 1997-01-10 1997-02-26 Biocompatibles Ltd Device for use in the eye
US5713844A (en) 1997-01-10 1998-02-03 Peyman; Gholam A. Device and method for regulating intraocular pressure
US5736491A (en) 1997-01-30 1998-04-07 Texaco Inc. Method of improving the fuel economy characteristics of a lubricant by friction reduction and compositions useful therein
US6002480A (en) 1997-06-02 1999-12-14 Izatt; Joseph A. Depth-resolved spectroscopic optical coherence tomography
DE19728069C1 (en) 1997-07-01 1999-02-11 Acritec Gmbh Device for measuring intraocular pressure
EP0898947A3 (en) 1997-08-15 1999-09-08 GRIESHABER & CO. AG SCHAFFHAUSEN Method and apparatus to improve the outflow of the aqueous humor of an eye
JPH1156897A (en) 1997-08-18 1999-03-02 Koken Co Ltd Collagen ophthalmologic surgery assisting agent
US5997531A (en) 1998-01-29 1999-12-07 Cardiodyne, Inc. User actuated laser energy device and procedure for forming a channel within tissue
US6083193A (en) 1998-03-10 2000-07-04 Allergan Sales, Inc. Thermal mode phaco apparatus and method
US6099521A (en) 1998-05-26 2000-08-08 Shadduck; John H. Semiconductor contact lens cooling system and technique for light-mediated eye therapies
US6319274B1 (en) 1998-06-22 2001-11-20 John H. Shadduck Devices and techniques for light-mediated stimulation of trabecular meshwork in glaucoma therapy
DE19840047B4 (en) 1998-09-02 2004-07-08 Neuhann, Thomas, Prof.Dr.med. Device for the targeted improvement and / or permanent guarantee of the permeability for eye chamber water through the trabecular mechanism in the Schlemm's Canal
US6146375A (en) 1998-12-02 2000-11-14 The University Of Michigan Device and method for internal surface sclerostomy
MXPA01010832A (en) 1999-04-26 2003-06-30 Gmp Vision Solutions Inc Shunt device and method for treating glaucoma.
DE19920615A1 (en) 1999-05-05 2000-12-07 Tui Laser Ag Device for treating glaucorn of the eye
KR100771149B1 (en) 1999-12-10 2007-10-30 아이싸이언스 인터벤셔날 코포레이션 Treatment of ocular disease
US6398809B1 (en) 2000-04-12 2002-06-04 Bausch & Lomb Incorporated Intraocular lens
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US6638239B1 (en) 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
DE60131273T2 (en) 2000-05-19 2008-08-28 Michael S. Beverly Hills Berlin LASER APPLICATION SYSTEM AND METHOD FOR EYE-USE
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
FR2813521B1 (en) 2000-09-01 2003-06-13 Ioltechnologie Production GLAUCOME DRAIN
DE10062478A1 (en) 2000-12-14 2002-07-04 Glautec Ag Glaucoma treatment device
WO2002056805A2 (en) 2001-01-18 2002-07-25 The Regents Of The University Of California Minimally invasive glaucoma surgical instrument and method
US6863667B2 (en) 2001-01-29 2005-03-08 Intralase Corp. Ocular fixation and stabilization device for ophthalmic surgical applications
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
EP1367968A4 (en) * 2001-03-16 2006-12-13 Glaukos Corp Applicator and methods for placing a trabecular shunt for glaucoma treatment
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
DE10118933A1 (en) 2001-04-18 2002-11-14 Glautec Ag Glaucoma treatment device
US6533769B2 (en) 2001-05-03 2003-03-18 Holmen Joergen Method for use in cataract surgery
US7331984B2 (en) * 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7027233B2 (en) 2001-10-12 2006-04-11 Intralase Corp. Closed-loop focal positioning system and method
US20030105456A1 (en) 2001-12-04 2003-06-05 J.T. Lin Apparatus and methods for prevention of age-related macular degeneration and other eye diseases
US20060200113A1 (en) 2002-03-07 2006-09-07 David Haffner Liquid jet for glaucoma treatment
WO2003082146A2 (en) 2002-03-23 2003-10-09 Intralase Corp. System and method for improved material processing using a laser beam
US20030236483A1 (en) 2002-06-25 2003-12-25 Ren David H Dual drainage ocular shunt for glaucoma
US7133137B2 (en) 2002-06-27 2006-11-07 Visx, Incorporated Integrated scanning and ocular tomography system and method
US6992765B2 (en) 2002-10-11 2006-01-31 Intralase Corp. Method and system for determining the alignment of a surface of a material in relation to a laser beam
US20040116909A1 (en) 2002-12-11 2004-06-17 Ceramoptec Industries Inc. Multipurpose diode laser system for ophthalmic laser treatments
US20040216749A1 (en) * 2003-01-23 2004-11-04 Hosheng Tu Vasomodulation during glaucoma surgery
US20050043722A1 (en) 2003-08-22 2005-02-24 Lin J. T. Methods and apparatus for treatment of eye disorders using articulated-arm-coupled ultraviolet lasers
US7704246B2 (en) 2004-04-30 2010-04-27 Connor Christopher S Shielded intraocular probe for improved illumination or therapeutic application of light
US20050279369A1 (en) 2004-06-21 2005-12-22 Lin J T Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation
WO2006015016A2 (en) 2004-07-30 2006-02-09 Massachusetts Eye And Ear Infirmary Photodynamic therapy and compositions for treating ocular glaucoma
US7584756B2 (en) 2004-08-17 2009-09-08 Amo Development, Llc Apparatus and method for correction of aberrations in laser system optics
US20060129141A1 (en) 2004-12-10 2006-06-15 Lin J T Treatment of eye disorders using articulated-arm coupled ultraviolet lasers
US20060224146A1 (en) 2005-03-30 2006-10-05 Lin J T Method and system for non-invasive treatment of hyperopia, presbyopia and glaucoma
US20060259021A1 (en) 2005-05-12 2006-11-16 Lin J T Diode-laser-pumped ultraviolet and infrared lasers for ablation and coagulation of soft tissue
US20070093794A1 (en) 2005-10-14 2007-04-26 Qi Wang Device, system and method for dual-path ophthalmic device
US7611507B2 (en) 2005-10-24 2009-11-03 Amo Development Llc Disposable patient interface
WO2007059292A2 (en) 2005-11-16 2007-05-24 Schachar Ronald A Apparatus and method for measuring scleral curvature and velocity of tissues of the eye
US20070173791A1 (en) 2006-01-20 2007-07-26 Intralase Corp. System for ophthalmic laser surgery
US9402714B2 (en) 2006-03-06 2016-08-02 Amo Development, Llc Method of transplanting a cornea
US20070219541A1 (en) 2006-03-14 2007-09-20 Intralase Corp. System and method for ophthalmic laser surgery on a cornea
US7522642B2 (en) 2006-03-29 2009-04-21 Amo Development Llc Method and system for laser amplification using a dual crystal Pockels cell
US8057463B2 (en) 2006-04-07 2011-11-15 Amo Development, Llc. Adaptive pattern correction for laser scanners
US7887532B2 (en) 2006-09-05 2011-02-15 Amo Development, Llc. System and method for resecting corneal tissue using non-continuous initial incisions
US20080082088A1 (en) 2006-09-05 2008-04-03 Intralase Corp. System and method for resecting corneal tissue
US8075552B2 (en) 2006-11-20 2011-12-13 Amo Development Llc. System and method for preparation of donor corneal tissue
US7575322B2 (en) 2007-05-11 2009-08-18 Amo Development Llc. Auto-alignment and auto-focus system and method
US9456925B2 (en) 2007-09-06 2016-10-04 Alcon Lensx, Inc. Photodisruptive laser treatment of the crystalline lens
EP2826436B1 (en) 2007-09-06 2018-03-28 Alcon LenSx, Inc. Precise targeting of surgical photodisruption
US20100324543A1 (en) 2007-09-18 2010-12-23 Kurtz Ronald M Method And Apparatus For Integrating Cataract Surgery With Glaucoma Or Astigmatism Surgery
ES2390315T3 (en) 2007-11-02 2012-11-08 Alcon Lensx, Inc. Apparatus for improved postoperative ocular optical performance
US20090118716A1 (en) 2007-11-07 2009-05-07 Intralase, Inc. System and method for scanning a pulsed laser beam
US8632526B2 (en) 2007-11-07 2014-01-21 Amo Development, Llc System and method of interfacing a surgical laser with an eye
US8142423B2 (en) 2007-11-07 2012-03-27 Amo Development, Llc. System and method for incising material
US8262647B2 (en) 2009-07-29 2012-09-11 Alcon Lensx, Inc. Optical system for ophthalmic surgical laser
US8419721B2 (en) 2009-07-29 2013-04-16 Alcon Lensx, Inc. Optical system for ophthalmic surgical laser
US8267925B2 (en) 2009-07-29 2012-09-18 Alcon Lensx, Inc. Optical system for ophthalmic surgical laser
US9504608B2 (en) 2009-07-29 2016-11-29 Alcon Lensx, Inc. Optical system with movable lens for ophthalmic surgical laser
WO2013095695A1 (en) 2011-04-10 2013-06-27 Vanessa Vera Systems and methods to deliver laser pulses into the eye
US20120283557A1 (en) * 2011-05-05 2012-11-08 Berlin Michael S Methods and Apparatuses for the Treatment of Glaucoma using visible and infrared ultrashort laser pulses

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199149A1 (en) * 1996-03-21 2004-10-07 Myers Raymond I. Lenticular refractive surgery of presbyopia, other refractive errors, and cataract retardation
US20080082078A1 (en) * 2001-05-21 2008-04-03 Eyelight, Inc. Glaucoma surgery methods and systems
US20060050229A1 (en) * 2003-04-07 2006-03-09 Arkadiy Farberov Universal gonioscope-contact lens system for intraocular laser surgery
US7125119B2 (en) * 2003-04-07 2006-10-24 Arkadiy Farberov Universal gonioscope-contact lens system for observation and intraocular laser surgery
US20090281530A1 (en) * 2005-06-13 2009-11-12 Technolas Perfect Vision Gmbh Messerschmittstrasse 1+3 Method for treating an organic material
US20080091224A1 (en) * 2006-07-11 2008-04-17 Refocus Group, Inc. Apparatus and method for securing ocular tissue
US20080027519A1 (en) * 2006-07-28 2008-01-31 Guerrero John M Method of treatment of ocular compartment syndromes
US20090157062A1 (en) * 2007-12-13 2009-06-18 Christoph Hauger Systems and methods for treating glaucoma and systems and methods for imaging a portion of an eye
US20100036488A1 (en) * 2008-04-04 2010-02-11 Forsight Labs, Llc Therapeutic device for pain management and vision

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Owen, David. A moving-mirror gonioscope for retinal surgery. 1977. British Journal of Ophthalmology, 61, 246-247. *

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485702B2 (en) 2000-04-14 2019-11-26 Glaukos Corporation System and method for treating an ocular disorder
US9993368B2 (en) 2000-04-14 2018-06-12 Glaukos Corporation System and method for treating an ocular disorder
US10383689B2 (en) 2000-05-19 2019-08-20 Michael S. Berlin Delivery system and method of use for the eye
US9833357B2 (en) 2000-05-19 2017-12-05 Michael S. Berlin Delivery system and method of use for the eye
US10687978B2 (en) 2000-05-19 2020-06-23 Ivantis, Inc. Delivery system and method of use for the eye
US10390993B1 (en) 2000-05-19 2019-08-27 Ivantis, Inc. Delivery system and method of use for the eye
US10335314B2 (en) 2000-05-19 2019-07-02 Ivantis, Inc. Delivery system and method of use for the eye
US10159601B2 (en) 2000-05-19 2018-12-25 Ivantis, Inc. Delivery system and method of use for the eye
US9820883B2 (en) 2000-05-19 2017-11-21 Michael S. Berlin Method for treating glaucoma
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US10195080B2 (en) 2000-05-19 2019-02-05 Michael S. Berlin Glaucoma surgery methods and systems
US9572963B2 (en) 2001-04-07 2017-02-21 Glaukos Corporation Ocular disorder treatment methods and systems
US10828473B2 (en) 2001-04-07 2020-11-10 Glaukos Corporation Ocular implant delivery system and methods thereof
US9987472B2 (en) 2001-04-07 2018-06-05 Glaukos Corporation Ocular implant delivery systems
US9642746B2 (en) 2001-05-21 2017-05-09 Michael Berlin Glaucoma surgery methods and systems
US10285856B2 (en) 2001-08-28 2019-05-14 Glaukos Corporation Implant delivery system and methods thereof for treating ocular disorders
US10485701B2 (en) 2002-04-08 2019-11-26 Glaukos Corporation Devices and methods for glaucoma treatment
US9962290B2 (en) 2006-11-10 2018-05-08 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US10828195B2 (en) 2006-11-10 2020-11-10 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US11744734B2 (en) 2007-09-24 2023-09-05 Alcon Inc. Method of implanting an ocular implant
US10363169B2 (en) 2010-05-10 2019-07-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. System and method for treating an eye
US10765559B2 (en) 2011-05-05 2020-09-08 Michael S. Berlin Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US10064757B2 (en) 2011-05-05 2018-09-04 Michael S. Berlin Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US11857463B2 (en) 2011-05-05 2024-01-02 Michael S. Berlin Methods for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US11510813B2 (en) 2011-05-05 2022-11-29 Michael S. Berlin Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US11039958B2 (en) 2011-05-05 2021-06-22 Michael S. Berlin Methods and apparatuses for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US10363168B2 (en) 2011-06-14 2019-07-30 Ivantis, Inc. Ocular implants for delivery into the eye
US20130204236A1 (en) * 2011-12-01 2013-08-08 Nanophthalmos, Llc Method and system for laser ocular surgery
US11135088B2 (en) 2011-12-19 2021-10-05 Ivantis Inc. Delivering ocular implants into the eye
US9358157B2 (en) 2012-02-28 2016-06-07 Ziemer Ophthalmic Systems Ag Apparatus for treating eye tissue with laser pulses
US8784406B2 (en) 2012-02-28 2014-07-22 Ziemer Ophthalmic Systems Ag Ophthalmological patient interface device
US20130226159A1 (en) * 2012-02-28 2013-08-29 Ziemer Ophthalmic Systems Ag Ophthalmological patient interface device
US11197780B2 (en) 2012-03-26 2021-12-14 Glaukos Corporation System and method for delivering multiple ocular implants
US11944573B2 (en) 2012-03-26 2024-04-02 Glaukos Corporation System and method for delivering multiple ocular implants
US9554940B2 (en) 2012-03-26 2017-01-31 Glaukos Corporation System and method for delivering multiple ocular implants
US10271989B2 (en) 2012-03-26 2019-04-30 Glaukos Corporation System and method for delivering multiple ocular implants
US11026836B2 (en) 2012-04-18 2021-06-08 Ivantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US11712369B2 (en) 2012-11-28 2023-08-01 Alcon Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
CN105050556A (en) * 2013-02-26 2015-11-11 贝尔金激光有限公司 System for glaucoma treatment
US10702416B2 (en) 2013-02-26 2020-07-07 Belkin Laser Ltd. System for glaucoma treatment
AU2014237841B2 (en) * 2013-03-15 2018-02-15 Amo Development, Llc. Hybrid ophthalmic interface apparatus
US10188551B2 (en) 2013-03-15 2019-01-29 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US11523938B2 (en) 2013-03-15 2022-12-13 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US11590025B2 (en) 2013-03-15 2023-02-28 Amo Development, Llc Hybrid ophthalmic interface apparatus
WO2014149772A3 (en) * 2013-03-15 2014-12-31 Amo Development, Llc. Hybrid ophthalmic interface apparatus
US10285853B2 (en) 2013-03-15 2019-05-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
US10898377B2 (en) 2013-03-15 2021-01-26 Amo Development, Llc Hybrid ophthalmic interface apparatus
US9795509B2 (en) 2013-03-15 2017-10-24 Amo Development, Llc Hybrid ophthalmic interface apparatus
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
US11197779B2 (en) 2015-08-14 2021-12-14 Ivantis, Inc. Ocular implant with pressure sensor and delivery system
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
US10258233B2 (en) * 2016-04-29 2019-04-16 Drug Delivery Company, Llc Non-sliding and non-sutured contact lens system for ophthalmic procedures
US11039746B1 (en) 2016-04-29 2021-06-22 Drug Delivery Company, Llc Non-sliding and non-sutured contact lens system for ophthalmic procedures
EP3449308A4 (en) * 2016-04-29 2020-03-25 Drug Delivery Company, LLC Non-sliding and non-sutured contact lens system for ophthalmic procedures
WO2018049359A1 (en) * 2016-09-12 2018-03-15 University Of Rochester Glaucoma surgery visualization apparatus
JP7185632B2 (en) 2017-02-15 2022-12-07 イリデックス・コーポレーション Method and ophthalmic mask device for treating eyes with broad-spectrum light source
JP2020507416A (en) * 2017-02-15 2020-03-12 イリデックス・コーポレーション Method for treating an eye using a wide area light source and an eye mask device
US10779990B2 (en) 2017-02-17 2020-09-22 EyeMDengineering LLC Ophthalmic incisional procedure instrument and method
JP2021000456A (en) * 2017-06-16 2021-01-07 エス. ベルリン、マイケル Methods and systems for oct-guided glaucoma surgery
US10993840B2 (en) 2017-06-16 2021-05-04 Michael S. Berlin Methods and systems for OCT guided glaucoma surgery
US11058584B2 (en) 2017-06-16 2021-07-13 Michael S. Berlin Methods and systems for OCT guided glaucoma surgery
WO2018232397A1 (en) 2017-06-16 2018-12-20 Berlin Michael S Methods and systems for oct guided glaucoma surgery
KR102556071B1 (en) 2017-06-16 2023-07-13 마이클 에스. 베를린 Systems for oct guided glaucoma surgery
US11918515B2 (en) 2017-06-16 2024-03-05 Michael S. Berlin Methods and systems for OCT guided glaucoma surgery
US10517760B2 (en) 2017-06-16 2019-12-31 Michael S. Berlin Methods and systems for OCT guided glaucoma surgery
KR20200138443A (en) * 2017-06-16 2020-12-09 마이클 에스. 베를린 Methods and systems for oct guided glaucoma surgery
US11819457B2 (en) 2017-06-16 2023-11-21 Michael S. Berlin Methods and systems for OCT guided glaucoma surgery
US11376040B2 (en) 2017-10-06 2022-07-05 Glaukos Corporation Systems and methods for delivering multiple ocular implants
USD846738S1 (en) 2017-10-27 2019-04-23 Glaukos Corporation Implant delivery apparatus
USD901683S1 (en) 2017-10-27 2020-11-10 Glaukos Corporation Implant delivery apparatus
USD938585S1 (en) 2017-10-27 2021-12-14 Glaukos Corporation Implant delivery apparatus
US11382794B2 (en) 2018-07-02 2022-07-12 Belkin Laser Ltd. Direct selective laser trabeculoplasty
US10821024B2 (en) 2018-07-16 2020-11-03 Vialase, Inc. System and method for angled optical access to the irido-corneal angle of the eye
US10821023B2 (en) 2018-07-16 2020-11-03 Vialase, Inc. Integrated surgical system and method for treatment in the irido-corneal angle of the eye
WO2020018436A1 (en) * 2018-07-16 2020-01-23 The Regents Of The University Of California Surgical treatment for glaucoma
JP7292390B2 (en) 2018-07-16 2023-06-16 ヴィアレーズ, インコーポレイテッド Integrated surgical system and method for treatment within the iridocorneal angle of the eye
US11666483B2 (en) 2018-07-16 2023-06-06 Vialase, Inc. System and method for angled optical access to the irido-corneal angle of the eye
US11246754B2 (en) 2018-07-16 2022-02-15 Vialase, Inc. Surgical system and procedure for treatment of the trabecular meshwork and Schlemm's canal using a femtosecond laser
US20200352785A1 (en) * 2018-07-16 2020-11-12 Vialase, Inc. Method, system, and apparatus for imaging and surgical scanning of the irido-corneal angle for laser surgery of glaucoma
US11583445B2 (en) 2018-09-07 2023-02-21 Vialase, Inc. Non-invasive and minimally invasive laser surgery for the reduction of intraocular pressure in the eye
WO2020050915A1 (en) * 2018-09-07 2020-03-12 Vialase, Inc. Non-invasive and minimally invasive laser surgery for the reduction of intraocular pressure in the eye
AU2019334845B2 (en) * 2018-09-07 2022-10-06 Vialase, Inc. Surgical system and procedure for precise intraocular pressure reduction
US11173067B2 (en) 2018-09-07 2021-11-16 Vialase, Inc. Surgical system and procedure for precise intraocular pressure reduction
US11110006B2 (en) 2018-09-07 2021-09-07 Vialase, Inc. Non-invasive and minimally invasive laser surgery for the reduction of intraocular pressure in the eye
WO2020050916A1 (en) * 2018-09-07 2020-03-12 Vialase, Inc. Surgical system and procedure for precise intraocular pressure reduction
US11654053B2 (en) 2018-09-07 2023-05-23 Vialase, Inc. Surgical system and procedure for precise intraocular pressure reduction
CN111110440A (en) * 2018-10-12 2020-05-08 北京弘健医疗器械有限公司 Device for performing scleral surgical procedures
EP3893824A4 (en) * 2018-12-13 2022-09-21 IOPtima Ltd. Methods and systems for laser assisted technology for minimally-invasive ab-interno glaucoma surgery
US11058582B2 (en) 2019-07-01 2021-07-13 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11318045B2 (en) 2019-07-01 2022-05-03 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11583443B2 (en) 2019-07-01 2023-02-21 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11590024B2 (en) 2019-07-01 2023-02-28 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11071647B2 (en) 2019-07-01 2021-07-27 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11583444B2 (en) 2019-07-01 2023-02-21 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11318047B2 (en) 2019-07-01 2022-05-03 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11318046B2 (en) 2019-07-01 2022-05-03 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11185443B2 (en) 2019-07-01 2021-11-30 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11850186B2 (en) 2019-07-01 2023-12-26 Michael S. Berlin Image guidance apparatus for glaucoma surgery
US11723805B2 (en) 2019-07-01 2023-08-15 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11185444B1 (en) 2019-07-01 2021-11-30 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11759357B2 (en) 2019-07-01 2023-09-19 Michael S. Berlin Image guidance apparatus for glaucoma surgery
US11191670B1 (en) 2019-07-01 2021-12-07 Michael S. Berlin Image guidance methods and apparatus for glaucoma surgery
US11564567B2 (en) * 2020-02-04 2023-01-31 Vialase, Inc. System and method for locating a surface of ocular tissue for glaucoma surgery based on dual aiming beams
US20210235986A1 (en) * 2020-02-04 2021-08-05 Vialase, Inc. System and method for locating a surface of ocular tissue for glaucoma surgery based on dual aiming beams
US11612315B2 (en) 2020-04-09 2023-03-28 Vialase, Inc. Alignment and diagnostic device and methods for imaging and surgery at the irido-corneal angle of the eye
WO2022056073A1 (en) * 2020-09-11 2022-03-17 ContactRx LLC Ophthalmic illumination device
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery

Also Published As

Publication number Publication date
US20190083314A1 (en) 2019-03-21
US20230165716A1 (en) 2023-06-01
US11039958B2 (en) 2021-06-22
US11510813B2 (en) 2022-11-29
US20200390604A1 (en) 2020-12-17
US20160095751A1 (en) 2016-04-07
US11857463B2 (en) 2024-01-02
US20210353464A1 (en) 2021-11-18
US10064757B2 (en) 2018-09-04
US20230355442A1 (en) 2023-11-09
US10765559B2 (en) 2020-09-08

Similar Documents

Publication Publication Date Title
US11857463B2 (en) Methods for the treatment of glaucoma using visible and infrared ultrashort laser pulses
US10687978B2 (en) Delivery system and method of use for the eye
US20210393438A1 (en) Device and method for laser assisted deep sclerectomy
US6251103B1 (en) Photoablative laser eye-treatment method
EP1286634B1 (en) Laser delivery system and method of use for the eye
US8679089B2 (en) Glaucoma surgery methods and systems
US20100324543A1 (en) Method And Apparatus For Integrating Cataract Surgery With Glaucoma Or Astigmatism Surgery
Palanker Ophthalmic Laser Therapy: Mechanisms and Applications
Mrochen et al. Laser Applications in Ophthalmology

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION